Conquering the final frontier in lung transplantation - Mesenchymal stromal cell therapy for chronic lung allograft dysfunction

征服肺移植的最后前沿——间充质基质细胞治疗慢性同种异体肺移植功能障碍

• 批准号: nhmrc : 1103789
• 负责人: A/Pr Daniel Chambers
• 金额: $ 130.38万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/conquering-final-frontier-allograft-dysfunction/662697
• 关键词: Conquering; final; frontier; lung; transplantation

Lung transplantation remains the only treatment option for an increasing number of Australians with end-stage lung disease, however long-term outcomes are severely compromised by the almost universal development of chronic rejection. Mesenchymal stromal cells (MSCs) hold great promise in treating rejection, and in a world-first we have recently demonstrated that this approach is safe. In another world-first, this randomized, controlled study will determine whether MSC therapy is effective.

肺移植仍然是越来越多的澳大利亚终末期肺病患者的唯一治疗选择，然而，长期结果受到几乎普遍的慢性排斥反应的严重影响。间充质基质细胞（MSC）在治疗排斥反应方面有很大的希望，我们最近首次证明了这种方法是安全的。在另一项世界首创的随机对照研究中，将确定MSC治疗是否有效。